Archives of Gynecology and Obstetrics

, Volume 274, Issue 2, pp 74–80

Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms

  • Diana Cieraad
  • Christian Conradt
  • Diana Jesinger
  • Marie Bakowski
Original Article

DOI: 10.1007/s00404-006-0132-4

Cite this article as:
Cieraad, D., Conradt, C., Jesinger, D. et al. Arch Gynecol Obstet (2006) 274: 74. doi:10.1007/s00404-006-0132-4

Abstract

A clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Objective: The objective of the study was to compare the effects of sequential 17β-oestradiol/dydrogesterone and conjugated equine oestrogens (CEE)/norgestrel on lipid parameters, climacteric symptoms, bleeding patterns and tolerability. Study design: This double-blind study was conducted in 193 peri- and post-menopausal women randomised to receive six, 28-day cycles of oral sequential oestradiol 1 mg/dydrogesterone 10 mg or CEE 0.625 mg/norgestrel 0.15 mg. The change from baseline in serum lipids and hot flushes was analysed using a two-way analysis of variance. Results: After 24 weeks there was a statistically significant increase in high-density lipoprotein (HDL) cholesterol in the oestradiol/dydrogesterone group and a significant reduction in the CEE/norgestrel group. The difference between the groups was significant (P=0.001). The number of hot flushes was reduced by 86% in both groups; this improvement was supported by the Greene Climacteric Symptom Scale score, the patients’ opinion and quality of life assessments. The percentage of women experiencing cyclic bleeding was greater with CEE/norgestrel, as was the mean duration and severity of bleeding. Both treatments were well tolerated. Conclusion: Oestradiol/dydrogesterone and CEE/norgestrel were equally effective in treating climacteric symptoms, but oestradiol/dydrogesterone showed some advantages in terms of lipid profile and incidence of bleeding.

Keywords

Hormone replacement therapyOestradiolDydrogesteroneConjugated equine oestrogenNorgestrel

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Diana Cieraad
    • 1
  • Christian Conradt
    • 2
  • Diana Jesinger
    • 3
  • Marie Bakowski
    • 3
  1. 1.Solvay Pharmaceuticals BVWeespThe Netherlands
  2. 2.Solvay Pharmaceuticals GmbHHannoverGermany
  3. 3.Solvay Healthcare LtdSouthamptonUK